Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC.ASMB · Entity 5216 | PFO and PAO | June 17, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ASSEMBLY BIOSCIENCES, INC.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,560 |
Reported balance
After 2026-06-17 transaction · row 1
1 source rowRow 1 · 2026-06-17 · Sale · Disposed 29 · Balance 14,560 F1: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sale is mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors that requires the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary transaction by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sale is mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors that requires the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary transaction by the reporting person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 18, 2026 20:05 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | SaleCommon Stock | 29 | $23.25 | $674.25 |
DisclosureSEC source: 0001193125-26-275804 · ownership.xml · nonDerivative · entry 1 Bjorkquist Jeanette M · CIK 0001945064 · PFO and PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,560 F1 · kind: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sale is mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors that requires the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary transaction by the reporting person. Read SEC document |
| March 30, 2026 Filed Mar 31, 2026 20:25 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | SaleCommon Stock | 16 | $27.49 | $439.84 |
DisclosureSEC source: 0001193125-26-134669 · ownership.xml · nonDerivative · entry 3 Bjorkquist Jeanette M · CIK 0001945064 · PFO and PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,089 F4 · kind: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sale is mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors that requires the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary transaction by the reporting person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.39 to $27.84, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within. Read SEC document |
| March 30, 2026 Filed Mar 31, 2026 20:25 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | SaleCommon Stock | 312 | $26.65 | $8,314.86 |
DisclosureSEC source: 0001193125-26-134669 · ownership.xml · nonDerivative · entry 2 Bjorkquist Jeanette M · CIK 0001945064 · PFO and PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,105 F4 · kind: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sale is mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors that requires the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary transaction by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.35 to $27.26, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within. Read SEC document |
| March 29, 2026 Filed Mar 31, 2026 20:25 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantCommon Stock | 6,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-134669 · ownership.xml · nonDerivative · entry 1 Bjorkquist Jeanette M · CIK 0001945064 · PFO and PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,417 F1 · shares: Grant of restricted stock units ("RSUs"). The RSUs vest in four equal installments, assuming continuous service on each vesting date, as follows: March 29, 2027; March 29, 2028; March 29, 2029; and March 29, 2030. F2 · shares: RSUs represent 65% of the reporting person's annual equity grant. The remaining 35% of the RSUs granted are contingent upon stockholder approval of an amendment to the Issuer's Amended and Restated 2018 Stock Incentive Plan (the "Plan") that increases the number of shares of common stock authorized for issuance under the Plan. F3 · balance_after: Reflects 300 fewer shares than were included in Column 5 on reporting person's prior Form 4 due to an administrative error. Read SEC document |
| March 29, 2026 Filed Jun 5, 2026 20:25 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantCommon Stock | 3,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-259661 · ownership.xml · nonDerivative · entry 1 Bjorkquist Jeanette M · CIK 0001945064 · PFO and PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,589 F1 · shares: Restricted stock units ("RSUs") representing 35% of the reporting person's annual equity grant, which was approved on March 29, 2026 and was contingent upon stockholder approval of an amendment to the Issuer's Amended and Restated 2018 Stock Incentive Plan (the "Plan") that increased the number of shares of common stock authorized for issuance under the Plan (the "Plan Amendment"). Although the RSUs were granted on March 29, 2026, the RSUs became issuable upon stockholder approval of the Plan Amendment on June 4, 2026 and vest in four approximately equal installments, assuming continuous service on each vesting date, as follows: March 29, 2027; March 29, 2028; March 29, 2029; and March 29, 2030. Read SEC document |
| June 16, 2025 Filed Jun 17, 2025 20:05 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 600 | $0.00 Strike: $17.24 | $0.00 |
DisclosureSEC source: 0000950170-25-087346 · ownership.xml · derivative · entry 2 Bjorkquist Jeanette M · CIK 0001945064 · PFO and PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600 Underlying: Common Stock · 600 shares Expires 2035-06-16 F2 · derivative.exercise_date: Grant of stock options. The stock options vest over four years, assuming continuous service on each vesting date, as follows: 25% vest on the first anniversary of the date of grant, June 16, 2026; and the remaining 75% vest in 36 approximately equal monthly installments, with the options becoming fully vested on June 16, 2029. Read SEC document |
| June 16, 2025 Filed Jun 17, 2025 20:05 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantCommon Stock | 300 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-087346 · ownership.xml · nonDerivative · entry 1 Bjorkquist Jeanette M · CIK 0001945064 · PFO and PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,097 F1 · shares: Grant of restricted stock units. The restricted stock units vest in four equal installments, assuming continuous service on each vesting date, as follows: June 16, 2026; June 16, 2027; June 16, 2028; and June 16, 2029. Read SEC document |
| March 31, 2025 Filed Apr 1, 2025 20:05 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | SaleCommon Stock | 180 | $9.85 | $1,772.66 |
DisclosureSEC source: 0000950170-25-048487 · ownership.xml · nonDerivative · entry 2 Bjorkquist Jeanette M · CIK 0001945064 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,617 F2 · kind: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sale is mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors that requires the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary transaction by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.56 to $10.40, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within. Read SEC document |
| March 29, 2025 Filed Apr 1, 2025 20:05 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 1,900 | $0.00 Strike: $10.62 | $0.00 |
DisclosureSEC source: 0000950170-25-048487 · ownership.xml · derivative · entry 3 Bjorkquist Jeanette M · CIK 0001945064 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,900 Underlying: Common Stock · 1,900 shares Expires 2035-03-29 F4 · derivative.exercise_date: Grant of stock options. The stock options vest over four years, assuming continuous service on each vesting date, as follows: 25% vest on the first anniversary of the date of grant, March 29, 2026; and the remaining 75% vest in 36 approximately equal monthly installments, with the options becoming fully vested on March 29, 2029. Read SEC document |
| March 29, 2025 Filed Apr 1, 2025 20:05 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantCommon Stock | 1,655 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-048487 · ownership.xml · nonDerivative · entry 1 Bjorkquist Jeanette M · CIK 0001945064 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,797 F1 · shares: Grant of restricted stock units. The restricted stock units vest in four approximately equal installments, assuming continuous service on each vesting date, as follows: March 29, 2026; March 29, 2027; March 29, 2028; and March 29, 2029. Read SEC document |
| May 23, 2024 Filed May 24, 2024 20:10 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | SaleCommon Stock | 24 | $14.93 | $358.41 |
DisclosureSEC source: 0000950170-24-064589 · ownership.xml · nonDerivative · entry 1 Bjorkquist Jeanette M · CIK 0001945064 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,142 F1 · kind: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sale is mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors that requires the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary transaction by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.74 to $15.20, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within. Read SEC document |
| April 01, 2024 Filed Apr 2, 2024 20:20 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | SaleCommon Stock | 114 | $13.07 | $1,490.20 |
DisclosureSEC source: 0000950170-24-040180 · ownership.xml · nonDerivative · entry 2 Bjorkquist Jeanette M · CIK 0001945064 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,166 F3 · kind: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sale is mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors that requires the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary transaction by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.90 to $13.30, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within. Read SEC document |
| March 29, 2024 Filed Apr 2, 2024 20:20 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 1,550 | $0.00 Strike: $13.30 | $0.00 |
DisclosureSEC source: 0000950170-24-040180 · ownership.xml · derivative · entry 3 Bjorkquist Jeanette M · CIK 0001945064 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,550 Underlying: Common Stock · 1,550 shares Expires 2034-03-29 F5 · derivative.exercise_date: Grant of stock options. The stock options vest over four years, assuming continuous service on each vesting date, as follows: 25% vest on the first anniversary of the date of grant, March 29, 2025; and the remaining 75% vest in 36 approximately equal monthly installments, with the options becoming fully vested on March 29, 2028. Read SEC document |
| March 29, 2024 Filed Apr 2, 2024 20:20 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantCommon Stock | 850 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-040180 · ownership.xml · nonDerivative · entry 1 Bjorkquist Jeanette M · CIK 0001945064 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,280 F1 · shares: Grant of restricted stock units. The restricted stock units vest in four approximately equal installments, assuming continuous service on each vesting date, as follows: March 29, 2025; March 29, 2026; March 29, 2027; and March 29, 2028. F2 · balance_after: Reflects equitable adjustment of the number of shares beneficially owned by the reporting person resulting from a 1-for-12 reverse stock split of the Issuer's common stock effected February 9, 2023, which is exempt from reporting pursuant to Rule 16a-9. Read SEC document |
| July 24, 2023 Filed Jul 25, 2023 20:30 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | SaleCommon Stock | 844 | $1.07 | $900.38 |
DisclosureSEC source: 0001209191-23-043309 · doc4.xml · nonDerivative · entry 1 Bjorkquist Jeanette M · CIK 0001945064 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,688 F1 · kind: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sale is mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors that requires the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary transaction by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.05 to $1.10, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within. Read SEC document |
| May 23, 2023 Filed May 24, 2023 21:10 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | SaleCommon Stock | 274 | $1.04 | $285.04 |
DisclosureSEC source: 0001209191-23-031918 · doc4.xml · nonDerivative · entry 2 Bjorkquist Jeanette M · CIK 0001945064 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,532 F3 · kind: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sale is mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors that requires the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary transaction by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.02 to $1.07, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within. Read SEC document |
| May 22, 2023 Filed May 24, 2023 21:10 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantCommon Stock | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-031918 · doc4.xml · nonDerivative · entry 1 Bjorkquist Jeanette M · CIK 0001945064 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,806 F1 · shares: Represents shares of common stock issuable under a performance-based restricted stock unit award dated July 22, 2021. On May 22, 2023, the performance-based vesting conditions were achieved. These shares of common stock vest in two equal installments, assuming continuous service on each vesting date, as follows: May 22, 2023 and May 22, 2024. F2 · balance_after: Includes 2,500 shares acquired under the Assembly Biosciences, Inc. Amended and Restated 2018 Employee Stock Purchase Plan on May 12, 2023. Read SEC document |
| March 30, 2023 Filed Mar 31, 2023 20:40 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | SaleCommon Stock | 774 | $0.82 | $637.16 |
DisclosureSEC source: 0001209191-23-021882 · doc4.xml · nonDerivative · entry 2 Bjorkquist Jeanette M · CIK 0001945064 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,806 F3 · kind: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors that requires the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary transaction by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.7795 to $0.89, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within. Read SEC document |
| March 29, 2023 Filed Mar 31, 2023 20:40 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $0.89 | $0.00 |
DisclosureSEC source: 0001209191-23-021882 · doc4.xml · derivative · entry 4 Bjorkquist Jeanette M · CIK 0001945064 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2033-03-29 F1 · derivative.exercise_date: Grant of restricted stock units. The restricted stock units vest in four equal installments, assuming continuous service on each vesting date, as follows: March 29, 2024; March 29, 2025; March 29, 2026; and March 29, 2027. Read SEC document |
| March 29, 2023 Filed Mar 31, 2023 20:40 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-021882 · doc4.xml · nonDerivative · entry 1 Bjorkquist Jeanette M · CIK 0001945064 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,580 F1 · shares: Grant of restricted stock units. The restricted stock units vest in four equal installments, assuming continuous service on each vesting date, as follows: March 29, 2024; March 29, 2025; March 29, 2026; and March 29, 2027. F2 · balance_after: Includes 2,500 shares acquired under the Assembly Biosciences, Inc. Amended and Restated 2018 Employee Stock Purchase Plan on November 14, 2022. Read SEC document |
| February 16, 2023 Filed Mar 31, 2023 20:40 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-23-021882 · doc4.xml · derivative · entry 3 Bjorkquist Jeanette M · CIK 0001945064 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2033-02-16 F5 · derivative.exercise_date: Grant of stock options. The stock options vest over four years, assuming continuous service on each vesting date, as follows: 25% vest on the first anniversary of the date of grant, February 16, 2024; and the remaining 75% vest in 36 approximately equal monthly installments, with the options becoming fully vested on February 16, 2027. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.